About Low-Grade Serous Ovarian Cancer (LGSOC)
Learn More About LGSOC
Low-grade serous ovarian cancer (LGSOC) is a subtype of ovarian cancer that is characterized by younger age at diagnosis and resistance to chemotherapy. It occurs in the epithelial cells that line the surface of the ovary.¹ Over 80% of patients who achieve full remission following first-line therapy will develop recurrent disease.²
Characteristics of LGSOC:
Represents 2-5% of all ovarian cancers 3
Typically diagnosed in women ~45 years of age 4,5
Associated with slow but persistent tumor growth 1
Approximately 70% of LGSOC tumors have RAS/MAPK pathway associated mutations, including KRAS mutations (~30%), NRAS/BRAF/ARAF mutations (~20%), and other RAS/MAPK-associated mutations (~20%) 4,5,6
Let’s Talk About LGSOC
The Let’s Talk About LGSOC initiative was created to be your source for information about LGSOC, including signs and symptoms, treatment options, and ways to connect to the LGSOC community. It also includes a range of resources to help address needs specific to people with LGSOC.
Grisham, R. Low grade serous carcinoma of the ovary. Oncology. 2016. 30(7):650-652. Available at: https://www.cancernetwork.com/view/low-grade-serous-carcinoma-ovary. Accessed December 3, 2020.
Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, Malpica A, Sun CC. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol. 2015 Aug 20;33(24):2675-82. doi: 10.1200/JCO.2015.61.0873. Epub 2015 Jul 20. PMID: 26195696; PMCID: PMC4534528.
Matsuo K, Machida H, Grubbs B, et al. Trends of low-grade serous ovarian carcinoma in the United States. J Gynecol Oncol. 2018;29(1):e15. doi:10.3802/jgo.2018.29.e15
Gershenson DM. Low-grade serous carcinoma of the ovary or peritoneum. Annals of Oncology 27 (Supplement 1): i45–i49, 2016. doi:10.1093/annonc/mdw085
Manning-Geist B, Gordhandas S, Liu YL, et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin Cancer Res. 2022;28:4456-4465. doi:10.1158/1078-0432.CCR-21-4183
Thomson JP, Hollis RL, van Baal J, et al. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome. Gynecol Oncol. 2023;174:157-166. doi:/10.1016/j.ygyno.2023.04.011
Redirection Notice
The information on this website is intended for US healthcare professionals only. Confirm you are a US healthcare professional to proceed.
Redirection Notice
The information on this website is intended for US healthcare professionals only. Confirm you are a US healthcare professional to proceed.